Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hypothetical protein | 0.0113 | 0.141 | 0.6931 |
Loa Loa (eye worm) | camk/mapkapk/mapkapk protein kinase | 0.0537 | 1 | 1 |
Brugia malayi | Phosphatidylinositol 3- and 4-kinase family protein | 0.0142 | 0.1997 | 0.1928 |
Schistosoma mansoni | phosphatidylinositol-45-bisphosphate 3-kinase catalytic subunit alpha PI3K | 0.0142 | 0.1997 | 0.1928 |
Entamoeba histolytica | phosphatidylinositol 3-kinase, putative | 0.0142 | 0.1997 | 1 |
Loa Loa (eye worm) | CMGC/MAPK/JNK protein kinase | 0.0421 | 0.765 | 0.765 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0421 | 0.765 | 0.7629 |
Trypanosoma cruzi | phosphatidylinositol 3-kinase 2, putative | 0.0142 | 0.1997 | 1 |
Echinococcus multilocularis | MAP kinase activated protein kinase 2 | 0.0537 | 1 | 1 |
Echinococcus multilocularis | phosphatidylinositol 4,5 bisphosphate 3 kinase | 0.0142 | 0.1997 | 0.1122 |
Loa Loa (eye worm) | phosphatidylinositol 3 | 0.0113 | 0.141 | 0.141 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0537 | 1 | 1 |
Giardia lamblia | Phosphoinositide-3-kinase, catalytic, alpha polypeptide | 0.0068 | 0.051 | 0.5 |
Trichomonas vaginalis | phosphatidylinositol 3-kinase catalytic subunit alpha, beta, delta, putative | 0.0097 | 0.1097 | 0.5294 |
Brugia malayi | Phosphatidylinositol 3- and 4-kinase family protein | 0.0092 | 0.0985 | 0.0907 |
Trichomonas vaginalis | phosphatidylinositol 3-kinase catalytic subunit gamma, putative | 0.0142 | 0.1997 | 1 |
Brugia malayi | Stress-activated protein kinase jnk-1 | 0.0421 | 0.765 | 0.7629 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.0136 | 0.0136 |
Echinococcus granulosus | phosphatidylinositol 45 bisphosphate 3 kinase | 0.0142 | 0.1997 | 0.1122 |
Entamoeba histolytica | phosphatidylinositol 3-kinase, putative | 0.0063 | 0.0398 | 0.1637 |
Loa Loa (eye worm) | hypothetical protein | 0.0092 | 0.0985 | 0.0985 |
Trypanosoma cruzi | phosphatidylinositol 3-kinase 2, putative | 0.0142 | 0.1997 | 1 |
Trypanosoma brucei | phosphatidylinositol 3-kinase, putative | 0.0047 | 0.0085 | 0.5 |
Entamoeba histolytica | phosphatidylinositol 3-kinase, putative | 0.0113 | 0.141 | 0.6931 |
Trypanosoma cruzi | phosphatidylinositol 3-kinase vps34-like | 0.0047 | 0.0085 | 0.0426 |
Echinococcus granulosus | MAP kinase activated protein kinase 2 | 0.0537 | 1 | 1 |
Echinococcus granulosus | c-Jun N-terminal kinases | 0.0421 | 0.765 | 0.7393 |
Trichomonas vaginalis | phosphatidylinositol kinase, putative | 0.0142 | 0.1997 | 1 |
Trichomonas vaginalis | phopsphatidylinositol 3-kinase, drosophila, putative | 0.0142 | 0.1997 | 1 |
Entamoeba histolytica | phosphatidylinositol 3-kinase 1, putative | 0.0138 | 0.1912 | 0.9555 |
Trichomonas vaginalis | phosphatidylinositol 3-kinase class, putative | 0.0097 | 0.1097 | 0.5294 |
Echinococcus multilocularis | c Jun NH2 terminal kinase | 0.0421 | 0.765 | 0.7393 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 42 nM | BindingDB_Patents: Biological Assay. The assay combines the scintillation proximity assay technology (SPA, Amersham) with the capacity of neomycin (a polycationic antibiotic) to bind phospholipids with high affinity and specificity. The Scintillation Proximity Assay is based on the properties of weakly emitting isotopes (such as 3H, 125I, 33P). Coating SPA beads with neomycin allows the detection of phosphorylated lipid substrates after incubation with recombinant PI3K and radioactive ATP in the same well, by capturing the radioactive phospholipids to the SPA beads through their specific binding to neomycin. | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.